APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell and Gene Therapy Enterprise Solutions

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cell and Gene Therapy Enterprise Solutions Market Outlook and Growth Opportunities 2026

28 December 2025203 pages

Choose your research edition.

Industry ResearchCell and Gene Therapy Enterprise Solutions Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell and Gene Therapy Enterprise Solutions Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Cell and Gene Therapy Enterprise Solutions Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell and Gene Therapy Enterprise Solutions Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell and Gene Therapy Enterprise Solutions Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Cell and Gene Therapy Enterprise Solutions market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell and Gene Therapy Enterprise Solutions is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cell and Gene Therapy Enterprise Solutions market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cell and Gene Therapy Enterprise Solutions market include Thermo Fisher Scientific, Miltenyi Biotec, Bruker Spatial Biology, Charles River Laboratories, Sartorius, Revvity, Red Cross Blood Services, Proteintech Group and Promega Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cell and Gene Therapy Enterprise Solutions market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell and Gene Therapy Enterprise Solutions and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell and Gene Therapy Enterprise Solutions revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell and Gene Therapy Enterprise Solutions market.

Cell and Gene Therapy Enterprise Solutions Segment by Company

Thermo Fisher Scientific

Miltenyi Biotec

Bruker Spatial Biology

Charles River Laboratories

Sartorius

Revvity

Red Cross Blood Services

Proteintech Group

Promega Corporation

BIOMÉRIEUX

QIAGEN

R&D Systems

Abcam

SGS

Azenta US

Vizient Inc

Cell and Gene Therapy Enterprise Solutions Segment by Type

Cell Therapy-Specific Solutions

Gene Therapy-Specific Solutions

Cell and Gene Therapy Enterprise Solutions Segment by Application

Academic/Research Lab

Biotech/Pharma Company

Clinical/Medical Institution

Cell and Gene Therapy Enterprise Solutions Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cell and Gene Therapy Enterprise Solutions status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cell and Gene Therapy Enterprise Solutions key companies, revenue, market share, and recent developments.

3. To split the Cell and Gene Therapy Enterprise Solutions breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cell and Gene Therapy Enterprise Solutions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cell and Gene Therapy Enterprise Solutions significant trends, drivers, influence factors in global and regions.

6. To analyze Cell and Gene Therapy Enterprise Solutions competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell and Gene Therapy Enterprise Solutions market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell and Gene Therapy Enterprise Solutions and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell and Gene Therapy Enterprise Solutions.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell and Gene Therapy Enterprise Solutions industry.

Chapter 3: Detailed analysis of Cell and Gene Therapy Enterprise Solutions company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cell and Gene Therapy Enterprise Solutions in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cell and Gene Therapy Enterprise Solutions in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cell and Gene Therapy Enterprise Solutions Industry Trends Table 2. Cell and Gene Therapy Enterprise Solutions Industry Drivers Table 3. Cell and Gene Therapy Enterprise Solutions Industry Opportunities and Challenges Table 4. Cell and Gene Therapy Enterprise Solutions Industry Restraints Table 5. Global Cell and Gene Therapy Enterprise Solutions Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cell and Gene Therapy Enterprise Solutions Revenue Share by Company (2021-2026) Table 7. Global Cell and Gene Therapy Enterprise Solutions Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cell and Gene Therapy Enterprise Solutions Key Company Manufacturing Base & Headquarters Table 9. Global Cell and Gene Therapy Enterprise Solutions Company, Product Type & Application Table 10. Global Cell and Gene Therapy Enterprise Solutions Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cell and Gene Therapy Enterprise Solutions by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cell Therapy-Specific Solutions Table 15. Significant Companies of Gene Therapy-Specific Solutions Table 16. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type (2021-2026) Table 20. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Academic/Research Lab Table 22. Significant Companies of Biotech/Pharma Company Table 23. Significant Companies of Clinical/Medical Institution Table 24. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application (2021-2026) Table 28. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application (2027-2032) Table 29. Global Cell and Gene Therapy Enterprise Solutions Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Region (2021-2026) Table 32. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Region (2027-2032) Table 34. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Cell and Gene Therapy Enterprise Solutions Sales Value Market Share by Country (2021-2026) Table 37. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Cell and Gene Therapy Enterprise Solutions Sales Value Market Share by Country (2027-2032) Table 39. Thermo Fisher Scientific Company Information Table 40. Thermo Fisher Scientific Business Overview Table 41. Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 43. Thermo Fisher Scientific Recent Development Table 44. Miltenyi Biotec Company Information Table 45. Miltenyi Biotec Business Overview Table 46. Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 48. Miltenyi Biotec Recent Development Table 49. Bruker Spatial Biology Company Information Table 50. Bruker Spatial Biology Business Overview Table 51. Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 53. Bruker Spatial Biology Recent Development Table 54. Charles River Laboratories Company Information Table 55. Charles River Laboratories Business Overview Table 56. Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 58. Charles River Laboratories Recent Development Table 59. Sartorius Company Information Table 60. Sartorius Business Overview Table 61. Sartorius Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 63. Sartorius Recent Development Table 64. Revvity Company Information Table 65. Revvity Business Overview Table 66. Revvity Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 68. Revvity Recent Development Table 69. Red Cross Blood Services Company Information Table 70. Red Cross Blood Services Business Overview Table 71. Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 73. Red Cross Blood Services Recent Development Table 74. Proteintech Group Company Information Table 75. Proteintech Group Business Overview Table 76. Proteintech Group Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 78. Proteintech Group Recent Development Table 79. Promega Corporation Company Information Table 80. Promega Corporation Business Overview Table 81. Promega Corporation Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 83. Promega Corporation Recent Development Table 84. BIOMÉRIEUX Company Information Table 85. BIOMÉRIEUX Business Overview Table 86. BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 88. BIOMÉRIEUX Recent Development Table 89. QIAGEN Company Information Table 90. QIAGEN Business Overview Table 91. QIAGEN Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 93. QIAGEN Recent Development Table 94. R&D Systems Company Information Table 95. R&D Systems Business Overview Table 96. R&D Systems Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 98. R&D Systems Recent Development Table 99. Abcam Company Information Table 100. Abcam Business Overview Table 101. Abcam Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 103. Abcam Recent Development Table 104. SGS Company Information Table 105. SGS Business Overview Table 106. SGS Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 108. SGS Recent Development Table 109. Azenta US Company Information Table 110. Azenta US Business Overview Table 111. Azenta US Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 113. Azenta US Recent Development Table 114. Vizient Inc Company Information Table 115. Vizient Inc Business Overview Table 116. Vizient Inc Cell and Gene Therapy Enterprise Solutions Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio Table 118. Vizient Inc Recent Development Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Cell and Gene Therapy Enterprise Solutions Product Image Figure 2. Global Cell and Gene Therapy Enterprise Solutions Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032) & (US$ Million) Figure 4. Global Cell and Gene Therapy Enterprise Solutions Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cell Therapy-Specific Solutions Image Figure 8. Gene Therapy-Specific Solutions Image Figure 9. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type (2021-2032) Figure 12. Academic/Research Lab Image Figure 13. Biotech/Pharma Company Image Figure 14. Clinical/Medical Institution Image Figure 15. Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application (2021-2032) Figure 18. Global Cell and Gene Therapy Enterprise Solutions Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032) & (US$ Million) Figure 21. North America Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032) & (US$ Million) Figure 27. South America Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Therapy-Specific Solutions
  • Gene Therapy-Specific Solutions
Applications
  • Academic/Research Lab
  • Biotech/Pharma Company
  • Clinical/Medical Institution
Companies covered
  • Thermo Fisher Scientific
  • Miltenyi Biotec
  • Bruker Spatial Biology
  • Charles River Laboratories
  • Sartorius
  • Revvity
  • Red Cross Blood Services
  • Proteintech Group
  • Promega Corporation
  • BIOMÉRIEUX
  • QIAGEN
  • R&D Systems
  • Abcam
  • SGS
  • Azenta US
  • Vizient Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cell and Gene Therapy Enterprise Solutions Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cell and Gene Therapy Enterprise Solutions Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cell and Gene Therapy Enterprise Solutions Market Dynamics
  1. 2.1 Cell and Gene Therapy Enterprise Solutions Industry Trends
  2. 2.2 Cell and Gene Therapy Enterprise Solutions Industry Drivers
  3. 2.3 Cell and Gene Therapy Enterprise Solutions Industry Opportunities and Challenges
  4. 2.4 Cell and Gene Therapy Enterprise Solutions Industry Restraints
3 Cell and Gene Therapy Enterprise Solutions Market by Company
  1. 3.1 Global Cell and Gene Therapy Enterprise Solutions Company Revenue Ranking in 2025
  2. 3.2 Global Cell and Gene Therapy Enterprise Solutions Revenue by Company (2021-2026)
  3. 3.3 Global Cell and Gene Therapy Enterprise Solutions Company Ranking (2024-2026)
  4. 3.4 Global Cell and Gene Therapy Enterprise Solutions Company Manufacturing Base and Headquarters
  5. 3.5 Global Cell and Gene Therapy Enterprise Solutions Company Product Type and Application
  6. 3.6 Global Cell and Gene Therapy Enterprise Solutions Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cell and Gene Therapy Enterprise Solutions Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cell and Gene Therapy Enterprise Solutions Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cell and Gene Therapy Enterprise Solutions Market by Type
  1. 4.1 Cell and Gene Therapy Enterprise Solutions Type Introduction
  2. 4.1.1 Cell Therapy-Specific Solutions
  3. 4.1.2 Gene Therapy-Specific Solutions
  4. 4.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type
  5. 4.2.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Type (2021-2032)
  7. 4.2.3 Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type (2021-2032)
5 Cell and Gene Therapy Enterprise Solutions Market by Application
  1. 5.1 Cell and Gene Therapy Enterprise Solutions Application Introduction
  2. 5.1.1 Academic/Research Lab
  3. 5.1.2 Biotech/Pharma Company
  4. 5.1.3 Clinical/Medical Institution
  5. 5.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application
  6. 5.2.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Application (2021-2032)
  8. 5.2.3 Global Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application (2021-2032)
6 Cell and Gene Therapy Enterprise Solutions Regional Value Analysis
  1. 6.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032)
  7. 6.3.2 North America Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032)
  10. 6.4.2 Europe Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032)
  16. 6.6.2 South America Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cell and Gene Therapy Enterprise Solutions Sales Value Share by Country, 2025 VS 2032
7 Cell and Gene Therapy Enterprise Solutions Country-level Value Analysis
  1. 7.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cell and Gene Therapy Enterprise Solutions Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cell and Gene Therapy Enterprise Solutions Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Thermo Fisher Scientific
  2. 8.1.1 Thermo Fisher Scientific Company Information
  3. 8.1.2 Thermo Fisher Scientific Business Overview
  4. 8.1.3 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Thermo Fisher Scientific Cell and Gene Therapy Enterprise Solutions Product Portfolio
  6. 8.1.5 Thermo Fisher Scientific Recent Developments
  7. 8.2 Miltenyi Biotec
  8. 8.2.1 Miltenyi Biotec Company Information
  9. 8.2.2 Miltenyi Biotec Business Overview
  10. 8.2.3 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Miltenyi Biotec Cell and Gene Therapy Enterprise Solutions Product Portfolio
  12. 8.2.5 Miltenyi Biotec Recent Developments
  13. 8.3 Bruker Spatial Biology
  14. 8.3.1 Bruker Spatial Biology Company Information
  15. 8.3.2 Bruker Spatial Biology Business Overview
  16. 8.3.3 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bruker Spatial Biology Cell and Gene Therapy Enterprise Solutions Product Portfolio
  18. 8.3.5 Bruker Spatial Biology Recent Developments
  19. 8.4 Charles River Laboratories
  20. 8.4.1 Charles River Laboratories Company Information
  21. 8.4.2 Charles River Laboratories Business Overview
  22. 8.4.3 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Charles River Laboratories Cell and Gene Therapy Enterprise Solutions Product Portfolio
  24. 8.4.5 Charles River Laboratories Recent Developments
  25. 8.5 Sartorius
  26. 8.5.1 Sartorius Company Information
  27. 8.5.2 Sartorius Business Overview
  28. 8.5.3 Sartorius Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sartorius Cell and Gene Therapy Enterprise Solutions Product Portfolio
  30. 8.5.5 Sartorius Recent Developments
  31. 8.6 Revvity
  32. 8.6.1 Revvity Company Information
  33. 8.6.2 Revvity Business Overview
  34. 8.6.3 Revvity Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Revvity Cell and Gene Therapy Enterprise Solutions Product Portfolio
  36. 8.6.5 Revvity Recent Developments
  37. 8.7 Red Cross Blood Services
  38. 8.7.1 Red Cross Blood Services Company Information
  39. 8.7.2 Red Cross Blood Services Business Overview
  40. 8.7.3 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Red Cross Blood Services Cell and Gene Therapy Enterprise Solutions Product Portfolio
  42. 8.7.5 Red Cross Blood Services Recent Developments
  43. 8.8 Proteintech Group
  44. 8.8.1 Proteintech Group Company Information
  45. 8.8.2 Proteintech Group Business Overview
  46. 8.8.3 Proteintech Group Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Proteintech Group Cell and Gene Therapy Enterprise Solutions Product Portfolio
  48. 8.8.5 Proteintech Group Recent Developments
  49. 8.9 Promega Corporation
  50. 8.9.1 Promega Corporation Company Information
  51. 8.9.2 Promega Corporation Business Overview
  52. 8.9.3 Promega Corporation Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Promega Corporation Cell and Gene Therapy Enterprise Solutions Product Portfolio
  54. 8.9.5 Promega Corporation Recent Developments
  55. 8.10 BIOMÉRIEUX
  56. 8.10.1 BIOMÉRIEUX Company Information
  57. 8.10.2 BIOMÉRIEUX Business Overview
  58. 8.10.3 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  59. 8.10.4 BIOMÉRIEUX Cell and Gene Therapy Enterprise Solutions Product Portfolio
  60. 8.10.5 BIOMÉRIEUX Recent Developments
  61. 8.11 QIAGEN
  62. 8.11.1 QIAGEN Company Information
  63. 8.11.2 QIAGEN Business Overview
  64. 8.11.3 QIAGEN Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  65. 8.11.4 QIAGEN Cell and Gene Therapy Enterprise Solutions Product Portfolio
  66. 8.11.5 QIAGEN Recent Developments
  67. 8.12 R&D Systems
  68. 8.12.1 R&D Systems Company Information
  69. 8.12.2 R&D Systems Business Overview
  70. 8.12.3 R&D Systems Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  71. 8.12.4 R&D Systems Cell and Gene Therapy Enterprise Solutions Product Portfolio
  72. 8.12.5 R&D Systems Recent Developments
  73. 8.13 Abcam
  74. 8.13.1 Abcam Company Information
  75. 8.13.2 Abcam Business Overview
  76. 8.13.3 Abcam Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Abcam Cell and Gene Therapy Enterprise Solutions Product Portfolio
  78. 8.13.5 Abcam Recent Developments
  79. 8.14 SGS
  80. 8.14.1 SGS Company Information
  81. 8.14.2 SGS Business Overview
  82. 8.14.3 SGS Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  83. 8.14.4 SGS Cell and Gene Therapy Enterprise Solutions Product Portfolio
  84. 8.14.5 SGS Recent Developments
  85. 8.15 Azenta US
  86. 8.15.1 Azenta US Company Information
  87. 8.15.2 Azenta US Business Overview
  88. 8.15.3 Azenta US Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Azenta US Cell and Gene Therapy Enterprise Solutions Product Portfolio
  90. 8.15.5 Azenta US Recent Developments
  91. 8.16 Vizient Inc
  92. 8.16.1 Vizient Inc Company Information
  93. 8.16.2 Vizient Inc Business Overview
  94. 8.16.3 Vizient Inc Cell and Gene Therapy Enterprise Solutions Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Vizient Inc Cell and Gene Therapy Enterprise Solutions Product Portfolio
  96. 8.16.5 Vizient Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst